A stock’s 52-week high and low prices can offer a wealth of information about its current standing and prospective future performance. Zentalis Pharmaceuticals Inc’s current trading price is -81.80% away from its 52-week high, while its distance from the 52-week low is 17.31%. The stock’s price range for this time frame has been between $2.83 and $18.24. The trading volume of the company’s shares in the Healthcare reached around 1.26 million for the day, which was evidently lower than the average daily volume of 1.78 million over the last three months.
Zentalis Pharmaceuticals Inc’s stock has seen a rocky market performance. The company’s stock achieved a 1-year high of $18.24 on 11/06/23, and the lowest price during that time was $2.83, recorded on 08/14/24.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
How Financial Performance Impacts Market Capitalization
Zentalis Pharmaceuticals Inc (ZNTL) has experienced a quarterly decline of -23.85% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 236.09M and boasts a workforce of 168 employees.
The Role of Moving Averages and Trading Volume in Technical Analysis
Based on Barchart.com data, the company’s moving average over the 100-day period was 4.34, with a change in price of -8.56. Similarly, Zentalis Pharmaceuticals Inc recorded 1,882,748 in trading volume during the last 100 days, posting a change of -72.05%.
How ZNTL’s Debt-to-Equity Ratio Affects Financial Health
A company’s financial condition and market reputation can be evaluated using the debt-to-equity (D/E) ratio. This ratio, calculated by dividing a company’s total liabilities by its shareholders’ equity, indicates the proportion of debt a company employs to back its assets in relation to its shareholders’ equity. At the time of writing, the total D/E ratio for ZNTL stands at 0.12. Similarly, the long-term debt-to-equity ratio is also 0.11.
ZNTL Stock Stochastic Average
Zentalis Pharmaceuticals Inc’s raw stochastic average for the past 50 days is currently at 18.77%. This represents a fall from the raw stochastic average of the last 20 days, which was recorded at 40.57%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 28.63% and 22.45%, respectively.
ZNTL Stock Price Performance Analysis
A mixed performance in the stock price over the year has left investors with either an optimistic or pessimistic outlook, depending on their point of view. Year to date metric has recorded a loss of -78.09%.However, over the last six months, we can see a stronger performance of -71.79%. Over the last 30 days, the price of ZNTL has leaped by -17.41%. And in the last five days, it has surged by 11.41%.
